Chromenopyrazole-Peptide Conjugates as Small-Molecule Based Inhibitors Disrupting the Protein-RNA Interaction of LIN28-let-7

Chembiochem. 2023 Sep 1;24(17):e202300376. doi: 10.1002/cbic.202300376. Epub 2023 Jul 27.

Abstract

Targeting the protein-RNA interaction of LIN28 and let-7 is a promising strategy for the development of novel anticancer therapeutics. However, a limited number of small-molecule inhibitors disrupting the LIN28-let-7 interaction with potent efficacy are available. Herein, we developed a novel LIN28-inhibiting strategy by targeting selective hotspot amino acids at the LIN28-let-7 binding interface with small-molecule-based bifunctional conjugates. Starting from reported small-molecule LIN28 inhibitors, we identified a feasible linker-attachment position after performing a structure-activity relationship exploration based on the LIN28-targeting chromenopyrazoles. In parallel, a virtual alanine scan identified hotspot residues at the protein-RNA binding interface, based on which we designed a set of peptides to enhance the interaction with the identified hotspot residues. Conjugation of the tailor-designed peptides with linker-attached chromenopyrazoles yielded a series of bifunctional small-molecule-peptide conjugates, represented by compound 83 (PH-223), as a new LIN28-targeting chemical modality. Our result demonstrated an unexplored rational design approach using bifunctional conjugates to target protein-RNA interactions.

Keywords: LIN28-let-7; RNA-binding protein; bifunctional conjugate; chromenopyrazole inhibitor; protein−RNA interaction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • MicroRNAs* / metabolism
  • Peptides / metabolism
  • Protein Binding
  • RNA-Binding Proteins* / metabolism

Substances

  • MicroRNAs
  • Peptides
  • mirnlet7 microRNA, human
  • Lin28A protein, human
  • RNA-Binding Proteins